Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water

Environmental Health Perspectives

Volumn 104, Issue 11, 1996, Pages 1200-1207

  Hopenhayn Rich, Claudia ^a   Biggs, Mary Lou ^a   Kalman, David A ^b   Moore, Lee E ^a   Smith, Allan H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Arsenic; Arsenic methylation; Arsenic speciation; Chile; Exposure change; Intervention studies; Water pollution

Indexed keywords

ARSENIC; BIOLOGICAL MARKER; CACODYLIC ACID; CARCINOGEN; DRINKING WATER; METHANEARSONIC ACID;

AGE; ARTICLE; CARCINOGENICITY; CHILE; ENVIRONMENTAL EXPOSURE; ETHNOLOGY; FOLLOW UP; GENDER; GENETIC POLYMORPHISM; METHYLATION; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; SMOKING; URINE LEVEL; WATER CONTAMINATION;

EID: 0030474176     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.961041200     Document Type: Article

References (39)

1. IARC. Arsenic and arsenic compounds. In: IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 23. Some metals and metallic compounds. Lyon, France:International Agency for Research on Cancer, 1980:39-141.
2. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol 135:462-476 (1992).
3. Wu M-M, Kuo T-L, Hwang Y-H, Chen C-J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 130: 1123-1132 (1989).
4. Chen C-J, Kuo T-L, Wu M-M. Arsenic and cancers [letter]. Lancet 1:414-415 (1988).
5. Hopenhayn-Rich C, Biggs ML, Fuchs A, Bergoglio R, Tello E, Nicolli H, Smith AH. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7:117-124 (1996).
6. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, Wood R, Kosnett MJ, Smith MT. Cancer risks from arsenic in drinking water. Environ Health Perspect 97:259-267 (1992).
7. Chen C-J, Chen CW, Wu M-M, Kuo T-L. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888-892 (1992).
8. U.S. EPA. Special report on ingested inorganic arsenic: skin cancer, nutritional essentiality. EPA/625/3-87/013. Washington:Environmental Protection Agency, 1988.
9. Vahter M. Species differences in the metabolism of arsenic compounds. Appl Organomet Chem 8:175-182 (1994).
10. Marcus WL, Rispin AS. Threshold carcinogenicity using arsenic as an example. In: Advances in modern environmental toxicology: risk assessment and risk management of industrial and environmental chemicals (Cothern CR, Mehlman MA, Marcus WL, eds). Princeton, NJ:Princeton Scientific Publishing, 1988;133-158.
11. ATSDR. Toxicological profile for arsenic, update. Report no. TP-92/102. Atlanta, GA:Agency for Toxic Substances and Disease Registry, 1993.
12. Mushak P, Crocetti A. Risk and revisionism in arsenic cancer risk assessment. Environ Health Perspect 103:684-689 (1995).
13. Tam GKH, Charbonneau SM, Bryce F, Pomroy C, Sandi E. Metabolism of inorganic arsenic (74As) in humans following oral ingestion. Toxicol Appl Pharmacol 50:319-322 (1979).
14. Vahter M. Metabolism of arsenic. In: Biological and environmental effects of arsenic (Fowler BA, ed). Amsterdam:Elsevier, 171-198;1983.
15. Hewitt DJ, Millner GC, Nye AC, Simmons HF. Investigation of arsenic exposure from soil at a Superfund site. Environ Res 68:73-81 (1995).
16. Buchet JP, Lauwerys R, Roels H. Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 48:111-118 (1981).
17. Hopenhayn-Rich C, Smith AH, Goeden HM. Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. Environ Res 60:161-177 (1993).
18. Warner ML, Moore LE, Smith MT, Kalman DA, Fanning E, Smith AH. Increased micronuclei in exfoliated bladder cells of persons who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol Biomarkers Prev 3:583-590 (1994).
19. Del Razo LM, Hernandez JL, Garcia-Vargas GG, Ostrosky-Wegman P, Cortinas de Nava C, Cebrian ME. Urinary excretion of arsenic species in a human population chronically exposed to arsenic via drinking water. A pilot study. In: Arsenic exposure and health (Chappell WR, Abernathy CO, Cothern CR, eds). Northwood, U.K.:Science and Technology Letters, 1994; 91-100.
20. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. Methylation study in a population environmentally exposed to high arsenic drinking water. Environ Health Perspect 104:620-628 (1996).
21. Sancha AM, Vega F, Venturino H, Fuentes S, Salazar AM, Moreno V, Baron AM, Rodriquez D. The arsenic health problem in northern Chile. Evaluation and control. A case study preliminary report. In: International seminar proceedings: arsenic in the environment and its incidence on health (Sancha AM, ed), 25-29 May 1992, Universidad de Chile, Facultad de Ciencias Fisicas y Matematicas, Santiago, Chile. 1992;187-202.
22. Alonso H. Arsenic enrichment in superficial waters. II. Region northern Chile. In: International Seminar Proceedings: arsenic in the environment and its incidence on health (Sancha AM, ed), 25-29 May 1992, Universidad de Chile, Facultad de Ciencias Fisicas y Matematicas, Santiago, Chile. 1992;101-108.
23. Moore LE, Smith AH, Hopenhayn-Rich C, Biggs ML, Kalman D, Smith MT. Micronuclei in exfoliated bladder cells among individuals chronically exposed to arsenic in drinking water. Cancer Epidemiol Biomarkers Prev (in press).
24. Biggs ML, Kalman DA, Moore LE, Hopenhayn-Rich C, Smith MT, Smith AH. Relationship of urinary arsenic to intake estimates and a biomarker of effect, bladder cell micronuclei. Mutat Res (in press).
25. Crecelius EA. Modification of the arsenic speciation technique using hydride generation. Anal Chem 50:826-827 (1978).
26. Atallah R, Kalman DA. On-line photooxidation for the determination of organoarsenic compounds by atomic absorption spectrophotometry with continuous arsine generation. Talanta 38:167-173 (1991).
27. Boeniger MF, Lowry LK, Rosenerg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J 54:615-627 (1993).
28. Carlson-Lynch H, Beck BD, Boardman PD. Arsenic risk assessment. Environ Health Perspect 102:354-356 (1994).
29. Crecelius EA. Changes in the chemical speciation of arsenic following ingestion by man. Environ Health Perspect 19:147-150 (1977).
30. Johnson LR, Farmer JG. Use of human metabolic studies and urinary arsenic speciation in assessing arsenic exposure. Bull Environ Contam Toxicol 46:53-61 (1991).
31. Buchet JP, Lauwerys R, Roels H. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health 48:71-79 (1981).
32. Buchet JP, Lauwerys R. Role of thiols in the in vitro methylation of inorganic arsenic by rat liver cytosol. Biochem Pharmacol 37:3149-3153 (1988).
33. Foa V, Colombi A, Maroni M, Buratti M, Calzaferri G. The speciation of the chemical forms of arsenic in the biological monitoring of exposure to inorganic arsenic. Sci Total Environ 34:241-259 (1984).
34. Vahter M, Lind B. Concentrations of arsenic in urine of the general population in Sweden. Sci Total Environ 54:1-12 (1986).
35. Buchet JP, Lauwerys R. Study of inorganic arsenic methyltion by rat liver in vitro: relevance for the interpretation of observations in man. Arch Toxicol 57:125-129 (1985).
36. Goyer RA. Toxic effects of metals. In: The basic science of poisons (Amdur MO, Doull J, Klaassen CD, eds). 4th ed. New York, USA:Pergamon Press, 1991;623-680.
37. Pacifici GM, Fracchia GN. Human methyltransferases, classification and metabolic profile of the major forms. The point of view of the clinical pharmacologist. In: Advances in drug metabolism in man (Pacifici GM, Fracchia GN, eds). Brussels, Luxembourg:European Commission, Directorate-General XIII Telecommunications, Information Market and Exploitation of Research, 1995;462-493.
38. Weinshilboum R. Pharmacogenetics of methylation: relationship to drug metabolism. Clin Biochem 21:201-210 (1988).
39. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen- metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85:1159-1164 (1993).